List view / Grid view
5 November 2014 | By The Institute of Cancer Research, London
A pioneering cancer drug set to become the first to be approved specifically for inherited cancers could also be used much more widely to treat prostate cancer, a world-leading expert has said...
5 November 2014 | By myoscience
myoscience, inc. is pleased to announce the appointment of Jeffrey Gold as Chief Executive Officer effective immediately...
4 November 2014 | By Photocure
Phase 2b results demonstrate significant and sustained efficacy in treating human papilloma virus and precancerous lesions of the cervix...
4 November 2014 | By Santen Pharmaceutical Co
Santen Pharmaceutical Co., Ltd. announced the establishment of a wholly owned subsidiary in The United Kingdom (UK) to serve customers and patients in the UK and Ireland...
4 November 2014 | By LEO Pharma and Japan Tobacco
LEO Pharma A/S and Japan Tobacco Inc. announced that the companies have entered into a license agreement, under which LEO Pharma will obtain exclusive rights to further develop, register and market JT’s experimental JAK inhibitor, JTE-052...
4 November 2014 | By Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited have announced that Marc Princen joined Takeda Pharmaceuticals International GmbH as Corporate Officer and President of the EUCAN (Europe and Canada) Business Unit...
4 November 2014 | By KMR Group
KMR Group, a leader in analyzing R&D performance data for the biopharmaceutical industry, has recently assessed the duration of oncology trials...
4 November 2014 | By The European CRO Federation
Patients, healthcare professionals and the public have the right to access clinical research information that may affect patients’ and public health, new and existing treatments of health conditions and access to innovative clinical research...
4 November 2014 | By ABIVAX
ABIVAX has appointed Karl Birthistle, M.D., and Daniel Kenny to its Executive Management team as VP of Global Regulatory Affairs and Chief Commercial Officer & VP of Business Development, respectively...
4 November 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company and Galecto Biotech AB have announced that the companies, together with the Galecto shareholders, have entered into an agreement that provides Bristol-Myers Squibb the exclusive option to acquire Galecto Biotech AB and gain worldwide rights to its lead asset TD139, a novel inhaled inhibitor of galectin-3 in…
4 November 2014 | By Andrew Lloyd & Associates
With few approved drugs available in SSc, this approach could significantly improve the treatment options in the future...
3 November 2014 | By Sartorius
Sartorius, a leading international laboratory and pharmaceutical equipment supplier, officially opened a new application center at its Shanghai office last week...
3 November 2014 | By kdm communications
The modular Asia flow chemistry system from Syrris proved key to the success of a recently described process for accelerated total synthesis of spirodienal A and spirangien A methyl ester...
3 November 2014 | By kdm communications
Cresset, innovative provider of computational chemistry software and services, is pleased to announce that Nagoya University’s Institute of Transformative Bio-Molecules (ITbM)...
3 November 2014 | By Auspherix Pty Ltd
Auspherix Pty Ltd, an early stage anti-infectives company developing novel antibiotics to treat resistant bacterial disease has secured a further with AU$1 million in a series A financing from Australia’s Medical Research Commercialisation Fund (MRCF), to progress its antibacterial compounds through development studies...
